Core Viewpoint - Hongxiang Co., Ltd. is facing legal actions due to false statements in its financial disclosures, leading to potential compensation claims from investors [1][6]. Group 1: Information Disclosure Violations - From 2017 to 2022, Hongxiang Co., Ltd. reported false financial information, including inflated sales and profits through fictitious business activities and asset overstatements [6]. - Specific financial manipulations include: - In 2017, inflated revenue of 104.89 million and profit of 59.72 million, representing 14.10% and 38.03% of reported figures respectively [6]. - In 2018, inflated revenue of 255.59 million and profit of 144.22 million, representing 19.49% and 47.72% of reported figures respectively [6]. - In 2019, inflated revenue of 227.07 million and profit of 141.18 million, representing 16.94% and 48.19% of reported figures respectively [6]. - In 2020, inflated revenue of 304.97 million and profit of 75.38 million, representing 20.12% and 29.79% of reported figures respectively [6]. - In 2021, inflated revenue of 108.80 million and a profit reduction of 0.33 million, representing 7.80% and 0.51% of reported figures respectively [6]. - In 2022, inflated costs of 24.88 million and a profit reduction of 24.88 million, representing 2.15% and 33.27% of reported figures respectively [6]. Group 2: Fraudulent Issuance - The company engaged in fraudulent activities during its 2019 private stock issuance [7]. - The 2020 public issuance of convertible bonds was also classified as fraudulent [8]. - Additionally, the 2020 announcement for issuing shares and cash for asset purchases contained significant false statements [9]. Group 3: Investor Compensation Claims - Investors who purchased Hongxiang Co., Ltd. shares between March 30, 2018, and April 29, 2023, and sold or held them after April 29, 2023, are eligible to file compensation claims [10].

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 上海久诚律师事务所投资者索赔律师许峰提示，天宜上佳（688033，天宜新材（维权））虚假陈述引发 的投资者索赔案还在持续推进中，如果投资者因此受损，目前还可发起索赔。（许峰律师专栏） 许峰律师代理的天宜上佳投资者索赔案已获得上海金融法院立案，目前正在等待法院的下一步安排，同 步还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托。根据法院送达的相关文 件，目前天宜上佳投资者索赔条件已初步确定。 2024年4月26日晚，天宜上佳公告收到北京证监局出具的《关于对北京天宜上佳高新材料股份有限公 司、杨铠璘、章丽娟采取出具警示函措施的决定》，经查，天宜上佳公司于2024年3月8日知悉，北京市 门头沟区监察委员会已对公司实际控制人、董事长吴佩芳实施留置。天宜上佳公司直至2024年3月15日 发布公告披露上述事项，信息披露不及时。 专门从事股票索赔 ...

2、相关定期报告存在重大遗漏。 3、"17凯撒03"债券相关定期报告存在重大遗漏。 上海久诚律师事务所股票索赔律师许峰提示，凯撒旅业（维权）（000796）虚假陈述引发的投资者索赔 案还在还在继续推进，如果投资者因此受损，目前还可发起索赔。凯撒旅业虚假陈述引发的投资者索赔 案已有投资者胜诉先例。（牛彬律师专栏） 2024年9月28日，凯撒旅业公告收到海南证监局《行政处罚决定书》，经查明，凯撒同盛存在以下违法 事实： 2020年1月至2022年12月，凯撒同盛通过资金拆借、应收款项被关联方代收、代关联方支付费用、委托 贷款、没有真实商业背景的股权投资及预付款项、保理放款等形式，与凯撒世嘉及其关联方发生非经营 性资金占用。截至2023年12月底，凯撒同盛上述资金占用情况已完成整改。具体违规包括： 1、未及时披露关联方非经营性资金占用。 专门从事股票索赔法律事务的上海久诚律师事务所主任许峰律师认为，在2020年1月8日到2023年9月5日 之间买入凯撒旅业股票，且在2023年9月5日后卖出或继续持有股票的投资者，目前还可发起索赔。（凯 撒旅业维权入口） （本文由上海久诚律师事务所主任许峰律师供稿，不代表新浪财经立场 ...

Group 1 - The Haikou Intermediate People's Court ruled in favor of investors in the case against Puli Pharmaceutical, allowing claims for those who purchased shares between April 26, 2022, and April 17, 2024, and sold or held shares after April 17, 2024 [1][2] - Puli Pharmaceutical was found to have overstated its revenue by approximately 514.6 million yuan in 2021, which accounted for 34.11% of the reported revenue for that year, and by about 515.9 million yuan in 2022, representing 28.56% of the reported revenue for that year [1] - The company also overstated its total profit by 308 million yuan in 2021, which was 65.88% of the reported total profit, and by 387.4 million yuan in 2022, which was 88.27% of the reported total profit [1] Group 2 - The law firm representing investors in Puli Pharmaceutical is also pursuing claims against Hainan Huatie, which is currently awaiting court arrangements after multiple submissions for case filing [2] - Hainan Huatie announced the termination of a contract for a computing power service agreement worth 3.69 billion yuan due to significant changes in market conditions since the contract was signed [3] - Investors who bought Hainan Huatie shares between March 5, 2025, and October 1, 2025, and sold or held shares after October 1, 2025, may also initiate claims [3]

Group 1: Peng Bo Shi (鹏博士) Case - Peng Bo Shi failed to disclose related party transactions as required [8] - Peng Bo Shi did not disclose significant contracts as mandated [8] - From 2012 to 2022, Peng Bo Shi's annual reports contained false records, including a profit inflation of 42,456,137.95 yuan in 2012, which accounted for 17.43% of that year's total profit [6][8] - Annual reports from 2012 to 2015 inflated assets, with the 2016 report inflating assets and profits by 162,000,000 yuan, representing 17.48% of that year's total profit [6][8] - From 2020 to 2022, Peng Bo Shi's annual reports reduced net assets by 196,000,000 yuan, which constituted 21.77%, 14.27%, and 18.51% of the net assets at the end of 2020, 2021, and 2022 respectively [2][6] Group 2: Investor Compensation - Investors who purchased Peng Bo Shi stock between April 12, 2013, and July 18, 2023, and sold or held the stock after July 18, 2023, may initiate claims for compensation [7] - The law firm representing investors in the Peng Bo Shi case has received a mediation agreement, allowing some investors to receive compensation [1][7] Group 3: Ning Ke Biological (宁科生物) Case - Ning Ke Biological's 2022 annual report contained false records, inflating revenue by 76,594,100 yuan and total profit by 77,222,000 yuan, which represented 11.25% and 46.59% of the respective totals [9] - The company failed to timely disclose significant events, including major debts and the freezing of key bank accounts [10][11] - Investors who bought Ning Ke Biological stock between November 22, 2022, and April 6, 2023, and sold or held the stock after April 6, 2023, as well as those who bought between April 28, 2023, and October 31, 2024, may also initiate claims for compensation [11]

Core Viewpoint - The article discusses recent legal developments regarding investor claims against Pulil Pharmaceutical and Hainan Huatie, highlighting the outcomes of court rulings and ongoing legal actions related to alleged financial misconduct by these companies. Group 1: Pulil Pharmaceutical - On December 23, 2025, the Haikou Intermediate People's Court ruled in favor of investors in a claim against Pulil Pharmaceutical, with the legal team continuing to accept further claims from other investors [1][4]. - Pulil Pharmaceutical was found to have overstated its revenue by approximately 514.6 million yuan in 2021, which accounted for 34.11% of the reported revenue for that year, and by about 515.9 million yuan in 2022, representing 28.56% of the reported revenue for that year [1][4]. - The company also overstated its total profit by 308 million yuan in 2021 (65.88% of reported profit) and by 387.4 million yuan in 2022 (88.27% of reported profit) [1][4]. Group 2: Hainan Huatie - Hainan Huatie's investor claims are also being pursued, with a new case submitted to the Hangzhou Intermediate People's Court on December 23, 2025, following previous submissions [2][5]. - The company received a notice from the China Securities Regulatory Commission on October 16, 2025, regarding an investigation into alleged violations of information disclosure laws [2][5]. - Hainan Huatie announced the termination of a "Computing Power Service Agreement" with a subsidiary, citing significant changes in market conditions and a lack of purchase orders since the contract was signed [3][6].

人民财讯12月24日电，12月24日，上海市高级人民法院发布《上海市高级人民法院关于为加快建设上海 国际金融中心提供司法服务保障的若干意见》。《若干意见》指出，上海高院将高效审理证券侵权纠纷 案件，强化"追首恶、惩帮凶"导向，准确认定上市公司控股股东、实际控制人首要责任，细化上市公 司、控股股东、董监高及中介机构过错认定与责任承担规则，畅通投资者向组织、指使虚假陈述者直接 索赔的路径，依法认定帮助造假者的民事赔偿责任。 ...

初步索赔范围： 凡于2021年9月6日至2025年12月20日期间买入卓然股份（688121）股票，且在2025年 12月20日之后卖出或继续持有的亏损投资者。（最终以法院裁决为准）（卓然股份维权入口） 登录新浪财经APP 搜索【信披】查看更多考评等级 2025年12月20日晚间，卓然股份（维权）发布《关于收到中国证券监督管理委员会立案告知书的公 告》。公告显示：上海卓然工程技术股份有限公司于近日收到中国证券监督管理委员会下发的《立案告 知书》。根据《立案告知书》，因公司涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华 人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案调查。 根据相关法律和司法实践，上海百悦律师事务所牛彬律师表示，卓然股份遭证监会立案，投资者或可索 赔。暂定：于2025年12月20日之前买入卓然股份股票，且在2025年12月21日之后卖出或继续持有该股票 的亏损投资者（包括投资机构），符合索赔条件。 索赔材料： 三、证券公司营业部出具的证券账户查询单； 一、买卖卓然股份688121股票的对账单原件 四、投资者的联系电话、地址及电子邮箱。 牛彬律师声明（牛彬律师专栏） 上述预登 ...

Core Viewpoint - Dongxu Optoelectronics Technology Co., Ltd. has been penalized by the China Securities Regulatory Commission (CSRC) for financial fraud, including inflating revenue and profits, and failing to disclose significant guarantees and lawsuits, leading to a change in its stock designation to "ST Dongxu" starting September 30, 2024 [1][4]. Summary by Sections Financial Misconduct - Between 2019 and 2022, Dongxu Optoelectronics engaged in financial misconduct by inflating revenue and profits, and underreporting asset impairment losses, resulting in false records in annual reports [1][4]. - The company also failed to timely disclose major guarantees and significant litigation, constituting multiple violations of information disclosure regulations [1][4]. Regulatory Actions - The CSRC has issued warnings and fines to the company and several responsible individuals, with some facing market entry bans [1][4]. - Starting September 30, 2024, the company's stock will be subject to additional risk warnings, and its stock name will change to "ST Dongxu" [1][4]. Investor Compensation - Investors who suffered losses due to Dongxu Optoelectronics' false statements can file lawsuits for compensation, as per the Securities Law and relevant judicial interpretations [1][4]. - The preliminary conditions for compensation include purchasing Dongxu Optoelectronics stock between February 15, 2016, and July 5, 2024, and selling or holding the stock after July 5, 2024 [2][4]. - Required documentation for claims includes original trading statements, copies of the investor's ID, confirmation of the securities account, and contact information [2][4].

Core Viewpoint - Xilong Science Co., Ltd. has been penalized for fabricating trade activities to inflate revenue and profits in its financial reports for 2020, 2021, and the first half of 2022, leading to a fine and accountability for responsible individuals [1][3]. Group 1: Company Actions and Legal Proceedings - On July 7, 2023, Xilong Science received an administrative penalty decision from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission [1][3]. - The fraudulent activities were revealed on April 29, 2023, when the company issued a correction announcement regarding prior accounting errors [4]. - On November 10, 2025, the Guangdong High People's Court upheld a ruling requiring the company to compensate 82 investors for losses amounting to over 7.57 million yuan [5]. Group 2: Investor Compensation and Legal Rights - Investors who suffered losses due to Xilong Science's false statements can file lawsuits for compensation based on the Securities Law and relevant judicial interpretations [2][5]. - The preliminary conditions for compensation include purchasing Xilong Science stock between April 29, 2021, and April 29, 2023, and selling or holding the stock after April 29, 2023 [2][5]. - Required documentation for claims includes original trading statements, copies of the investor's ID, a confirmation of the securities account, and contact information [2][5].